Blog - Page 408 of 5636 - QualityStocks

WednesdayJul 31, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss Study

Lexaria, a global innovator in drug delivery platforms, has released interim results from its WEIGHT-A24-1 animal study The study sought to explore the impact of its patented DehydraTECH technology on glucagon-like peptide-1 (“GLP-1”) drugs for the potential treatment of diabetes and weight loss, representing a major global market The first 28 days of dosing yielded positive results that Lexaria’s management described as “noteworthy” It also marked a significant milestone for the company and the first time it has used liraglutide in any of its GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery enhancement, just released interim…

TuesdayJul 30, 2024 2:23 pm

QualityStocksNewsBreaks – PayPal Holdings Inc. (NASDAQ: PYPL) Surpasses Quarterly Earnings Expectations

PayPal Holdings (NASDAQ: PYPL), a leading digital payments platform, recently reported its quarterly earnings, showcasing a performance that exceeded expectations. The company announced earnings of $1.19 per share, surpassing the Zacks Consensus Estimate of $0.96 per share. This marks an improvement from the $1.16 per share reported a year ago, representing an earnings surprise of nearly 24%. PayPal’s ability to consistently outperform consensus EPS estimates over the last four quarters highlights its robust financial health and operational efficiency. For the quarter ending in June 2024, PayPal posted revenues of $7.89 billion, exceeding the Zacks Consensus Estimate by 1.04%. This revenue figure represents…

TuesdayJul 30, 2024 11:48 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot study. The company reported that results from the study confirm improvements in cognitive function, memory and locomotor activity and show statistical significance in certain behavioral assessments.According to the announcement, InMed is moving forward with additional molecular analyses to better define the mechanisms of action and…

TuesdayJul 30, 2024 11:15 am

Canada’s Mining Legacy Continues: Torr Metals Inc. (TSX.V: TMET) and Quesnel Terrane Hold Promise for New Discoveries

In 2022, Canadian mines produced 510,782 tonnes of copper in concentrate, with over half originating from British Columbia The Quesnel Terrane, which is home to Torr Metals’ expansive Kolos Copper-Gold Project, has the potential to be instrumental in Canada’s next great copper discoveries Torr’s recent rock sampling confirmed copper porphyry mineralization in outcrop adjacent to Highway 5 in the heart of the southern Quesnel Terrane, with assays returning economic values as high as 4,240 ppm Cu and 1.07 g/t Au Canada stands as a global mining titan, amidst British Columbia becoming the largest copper producer, commanding 53% of total Canadian…

TuesdayJul 30, 2024 10:31 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into an exclusive license agreement with Cortice Biosciences Inc. Through the agreement, CNS Pharmaceuticals has acquired a license as well as the intellectual property rights to a potentially blood-brain-barrier, permeable microtubule inhibitor called TPI 287. The inhibitor is being developed for the treatment of glioblastoma multiforme (“GBM”). In return for the license, CNS Pharmaceuticals will pay Cortice an up-front payment of 616,698 shares of its common stock, as well as the possibility…

TuesdayJul 30, 2024 10:30 am

Correlate Energy Corp. (CIPI) Building Toward NYSE Uplist as it Meets Opportunities of Decentralized Energy Trend

Distributed energy solutions developer Correlate Energy Corp. helps clients find an affordable way to step up their energy use infrastructure through retrofit upgrades, taking advantage of a variety of financial incentives Decentralized energy generation has been trending as groups throughout the country search for ways to reduce carbon emissions and secure their power supply amid utility outages Correlate’s success is evident in its growing list of project fulfillments and growing revenue targets — $45 million to $60 million with 25 percent gross margins this year The company is working to uplist to the New York Stock Exchange, using a $7…

TuesdayJul 30, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials

Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process The company’s goal is to use this technology to restore brain function and improve the quality of life for patients dealing with neurodegenerative disease such as Alzheimer’s disease The worldwide market for Alzheimer's disease modifying drugs, versus symptomatic drugs, could approach $30 billion by 2030 Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S.…

TuesdayJul 30, 2024 9:00 am

SuperCom Ltd. (NASDAQ: SPCB) EM Technology Highly Competitive in Expanding Field of Court-administered Offender Monitoring

Cost-effective and recidivism-reducing alternatives to incarceration continue to occupy a priority for criminal justice systems worldwide as societies grapple with balancing concerns ranging from minimizing threats to sustaining positive work and family environments During the past four decades, electronic monitoring has emerged as a way to help individuals continue functioning positively within their communities after they have been convicted of criminal behavior Israel-based SuperCom Ltd. is positioning itself to be competitive in a field of related government-ordered service contracts, developing a suite of secure identification and digital monitoring products as an end-to-end solution for electronic monitoring programs The company is…

MondayJul 29, 2024 1:48 pm

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives Order for Mullen Campus EVs from Leading Transportation and Logistics Company

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for four Mullen Campus electric vehicles from DB Schenker, one of the world’s leading transportation and logistics companies. According to the announcement, the vehicles will be used for mail and delivery on Intel’s technology campus in Chandler, Arizona. The order was received through one of Mullen’s commercial vehicle dealers, Randy Marion Automotive. The dealer has received payment for the vehicles, and the vehicles have been delivered to DB Schenker. According to the company, the Mullen Campus is a highly efficient electric van designed for low-speed, closed-campus use.…

MondayJul 29, 2024 1:00 pm

QualityStocksNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Enters Definitive Agreement to Embark on New Journey Together with Koito

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions, is announcing the signing of a definitive agreement. The agreement provides for the acquisition of Cepton by Koito Manufacturing Co. Ltd. (TSE: 7276), a leading automotive tier one supplier. Specifically, Koito will acquire all the outstanding capital stock of Cepton not owned by itself in an all-cash transaction, with Cepton stockholders receiving $3.17 per share in cash. According to the announcement, the proposed transaction has been approved by each company’s Board of Directors and recommended to Cepton’s stockholders by Cepton’s Board of Directors. It is expected…

Site Search

Company Search